You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥(03347.HK)預計年度淨利潤增長50%至73%
格隆匯 01-12 19:39

格隆匯1月12日丨泰格醫藥(03347.HK)發佈公吿,2021年1月1日至2021年12月31日,公司預計歸屬於公司股東的淨利潤人民幣262,466.22萬元至人民幣302,711.04萬元,比上年同期增長50%至73%;預計扣除非經常性損益後的淨利潤人民幣113,310.56萬元至人民幣132,431.72萬元,比上年同期增長60%至87%。

報吿期內,公司主營業務持續增長,預計2021年度營業收入和歸屬於股東的淨利潤均較上年同期有所增長。公司2020年年度非經常性損益為人民幣104,158.38萬元,而於報吿期內,公司非經常性損益為約人民幣140,000萬元至人民幣180,000萬元,主要由於公司按照新金融工具準則確認的金融資產公允價值變動收益和取得股權轉讓收益所致,公司投資的金融資產主要為生物醫藥、醫療器械等與公司主營業務相關的公司以及醫療健康專業投資基金,其中公司直接或間接投資的生物醫藥、醫療器械以及與公司主營業務相關公司按照新金融工具準則確認的公允價值變動收益為約人民幣120,000萬元至人民幣160,000萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account